Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Krystal Biotech (KRYS) Income from Continuing Operations (2021 - 2025)

Krystal Biotech (KRYS) has disclosed Income from Continuing Operations for 5 consecutive years, with 51391000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations rose 12.91% to 51391000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 204824000.0 through Dec 2025, up 129.67% year-over-year, with the annual reading at 204831000.0 for FY2025, 129.74% up from the prior year.
  • Income from Continuing Operations hit 51391000.0 in Q4 2025 for Krystal Biotech, down from 79367000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 80747000.0 in Q3 2023 to a low of 49965000.0 in Q1 2022.
  • Historically, Income from Continuing Operations has averaged 4769650.0 across 5 years, with a median of 7328500.0 in 2021.
  • Biggest five-year swings in Income from Continuing Operations: crashed 215.99% in 2022 and later surged 3734.01% in 2025.
  • Year by year, Income from Continuing Operations stood at 21806000.0 in 2021, then crashed by 46.99% to 32052000.0 in 2022, then surged by 127.12% to 8692000.0 in 2023, then soared by 423.62% to 45513000.0 in 2024, then rose by 12.91% to 51391000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for KRYS at 51391000.0 in Q4 2025, 79367000.0 in Q3 2025, and 38333000.0 in Q2 2025.